Pathology: breast cancer - adjuvant; es-BC - TNBC - NA - all population; mBC - TNBC - L2 - all population; mBC - TNBC - L2 - PDL1 positive;
| breast cancer - adjuvant | es-BC - TNBC - NA - all population | mBC - TNBC - L2 - all population | mBC - TNBC - L2 - PDL1 positive | |||
| KEYNOTE-522, 2020 | KEYNOTE-522, 2020 | KEYNOTE-119 (all population), 2019 | KEYNOTE-119 (PDL1 CPS>10), 2019 | KEYNOTE-119 (PDL1 CPS>1), 2019 | ||
| pembrolizumab alone | 5 | T1 | T1 | T1 | T1 | T1 |
| placebo | 0 | T0 | T0 | |||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 |